Arizona State Retirement System Makes New $183,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Arizona State Retirement System bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 47,096 shares of the biotechnology company’s stock, valued at approximately $183,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Virtu Financial LLC acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $34,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $35,000. Robeco Institutional Asset Management B.V. acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $42,000. Verdence Capital Advisors LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $46,000. Finally, Creative Planning acquired a new stake in shares of ADMA Biologics in the third quarter valued at approximately $53,000. 71.17% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $4.03 on Thursday. The company has a quick ratio of 2.73, a current ratio of 7.19 and a debt-to-equity ratio of 1.06. The company has a market cap of $895.75 million, a P/E ratio of -16.79 and a beta of 0.91. ADMA Biologics, Inc. has a fifty-two week low of $1.84 and a fifty-two week high of $4.30. The firm’s 50 day moving average is $3.46 and its two-hundred day moving average is $3.46.

ADMA Biologics (NASDAQ:ADMA – Get Rating) last posted its quarterly earnings results on Thursday, March 23rd. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The company had revenue of $49.98 million for the quarter, compared to the consensus estimate of $49.02 million. ADMA Biologics had a negative net margin of 26.22% and a negative return on equity of 37.22%. During the same quarter last year, the firm posted ($0.09) earnings per share. Analysts expect that ADMA Biologics, Inc. will post -0.09 EPS for the current year.

Analyst Upgrades and Downgrades

ADMA has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of ADMA Biologics in a research report on Wednesday, February 8th. TheStreet raised shares of ADMA Biologics from a “d” rating to a “c-” rating in a research note on Friday, May 19th. Finally, StockNews.com began coverage on shares of ADMA Biologics in a research note on Thursday, May 18th. They set a “sell” rating on the stock.

About ADMA Biologics

(Get Rating)

ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.